Morbid ObesityNCT01063127
A Longitudinal Study on Short-term Effects of Gastric Bypass on Glucose Homeostasis in Obesity
An observational study of Morbid Obesity, run by Catholic University of the Sacred Heart at 1 site in Italy.
Trial summary
The purpose of this study is to quantify the relative contribution of improved insulin sensitivity and improved insulin secretion to the glycaemic effect of bariatric surgery. Read more about this study
- Who is it for?
- Ages 25 to 55 years
- Conditions the study is for
- Morbid Obesity
- What is being tested?
- Study on insulin sensitivity after diet or bariatric surgery and gastric bypass
- How many people
- 23 participants
- Where
- 1 siteItaly
- Study dates
- Feb 2010to Jul 2012
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 25 to 55 years
- All sexes
- No healthy volunteers
- Adult
Study population: Twenty morbidly obese subjects scheduled for RYGB or LAGB for will be included in the study.
Who may be able to join
- Morbidly obese subjects of both sexes with a BMI >40 kg/m2 who, for their obesity disease, are eligible for bariatric surgery and have accepted to undergo RYGB or LAGB
- Confirmed insulin resistance as assessed by Matsuda index
- Age 25-55 years
- Weight stable for at least 6 months before the study (+/- 5 kg within the previous 6 months)
- Stable medication
- Provision of informed consent, statistical analysis, and publications of obtained results
Who cannot join
- Patients not eligible for laparoscopic RYGB or LAGB
- Incapacity to give a valid informed consent or unwilling to give the consent
- Pregnancy or lactating
- Patients eligible for RYGB/LAGB, but with:
- Type 2-diabetes mellitus
- Significant illness within the two weeks preceding surgery, as judged by the physician.
- Obvious infection (bacteria, virus etc)
- Major cardiovascular disease
Trial locations and contacts
1 site in 1 country.
About this study
Official title: A Longitudinal, Open-label Study on the Short-term Effects of Roux-en-Y Gastric Bypass Surgery vs. Gastric Banding on Glucose Homeostasis in Obese Subjects
The purpose of this study is to quantify the relative contribution of improved insulin sensitivity and improved insulin secretion to the glycaemic effect of bariatric surgery.
Read the detailed description
In 1987 Pories et al. (1) published that after gastric bypass 99% of morbidly obese patients became and remained euglycaemic over time. However, the most interesting observation of these authors (1) was that the patients were converted to euglycaemia within 10 days of the operation, even if before they required large doses of insulin. Thereafter, we ourselves (2-6) as well as other Authors (7,8) have found that both mainly malabsorptive bariatric and mainly restrictive surgery are effective in producing early improvement/resolution of type 2 diabetes, also in normal weight (9) or overweight-obese subjects (10).
Until now the mechanisms through which bariatric surgery operate in improving insulin sensitivity and, consequently, diabetes control have not been elucidated. To complicate the picture there is the fact that after bariatric surgery patients are not allowed to eat for a time that is longer as the entity of the abdominal trauma increases. In fact, after laparoscopic bariatric surgery the patients are re-alimented in the 3rd post-operative day while after open surgery the time length before re-alimentation is about 7 days. Although in most centres the patients receive a parenteral nutrition covering the energy needs while they remain at rest, in some other centres they are only re-hydrated. Thus, it might be hypothesised that fasting can contribute to the improvement of glucose disposal. The data in the literature counteract this possibility as many Authors (11-15) have demonstrated that a very-low calorie diet (VLCD) is essentially unable to improve insulin sensitivity at least in the short run, when the weight loss is minimal. In this regard, Jazet et al. (11) found that the glucose control amelioration in diabetic subjects undergoing a 2-day VLCD was a reduction in the hepatic glucose production rather than an improvement in the whole-body glucose disposal. Similarly, Christiansen et al (12) observed the increase in the glucose metabolic clearance rate (MCR) was not apparent before day 20 of energy restriction, when the weight loss became significant. In another study, diabetic patients under a 4-day energy-restricted diet (providing 4620 ± 1050 kJ/d) had a deterioration of both basal glucose MCR and insulin-stimulated glucose disposal (13).
Recently, Laferrère et al (16) compared the late (1 month) effect of an equivalent weight loss by RYGB or by diet in two groups of matched morbidly obese patients with type 2 diabetes mellitus. The glucose area under-the-curve (AUC) after an oral glucose tolerance test (OGTT) and glucose levels at 120' were significantly lower after RYGB compared with diet (P = 0.014 and P = 0.001, respectively).
Another important aspect of the weight loss is the modulation of lipolysis. Many studies have shown that obese subjects are insulin resistant at the level of adipose tissue, ie, despite high plasma insulin levels lipolysis and FFA release are not suppressed. It is therefore interesting to study the changes in lipolysis before and after surgery and also the ability of insulin (e.g., during the euglycemic, hyperinsulinemic clamp) to suppress peripheral lipolysis. By infusing deuterated glycerol we will be able to estimate glycerol rate of appearance, which is the best available index of lipolysis. In fact intracellular triglyceride (TG) hydrolysis results in the release of one mole of glycerol and 3 moles of FFA. While the FFA can be re-esterified intracellularly, and thus do not appear into the systemic circulation, glycerol cannot be re-esterified since the adipocyte lacks glycerol kinase. Thus, all glycerol derived from intracellular TG hydrolysis is released into the circulation and can be traced by deuterated glycerol. We have used this technique previously in diabetic subjects (17), in subjects with NASH as well as in obese subjects under VLCD (18). In the latter study we have shown that VLCD improved adipose tissue IR.
As far as we know, no data are available in the literature comparing the effect of RYGB with a purely restrictive bariatric procedure in order to take into account simultaneously the effect of the surgical trauma and that of the reduced food intake in the early post-operative period.
The main goal of this study is to determine the immediate effect of Roux-en-Y gastric bypass surgery on glucose homeostasis, factoring out the confounding effects of the surgical approach (incl. laparoscopy) and of the post-operative fasting.
To this purpose, patients of the two bariatric surgery groups (Roux-en-Y gastric bypass and gastric banding) are matched as far as feasible. Primary parameter is insulin resistance (as assessed by Matsuda index). Further the same BMI inclusion criteria apply for both groups (BMI > 30 kg/m2 and < 55 kg/m2). While age, gender and BMI within the specified range are also expected to influence the read-outs, no matching for these baseline characteristics is foreseen due to feasibility issues.
Patients receive oral food typically from day 3 or 4 after laparoscopic bariatric surgery. This post-operative food intake is restricted to 800 - 1000 kcal/day, usually divided in 6 small meals, with the following composition 55% carbohydrates, 30% lipids and 15% proteins; saturated lipids ~ 10% . A similar caloric intake restriction will be imposed during the 1-week diet period prior to Visit 3, which will be done 10 +/- 2 weeks before the operation in order to allow the patients a complete recovery of his/her body weight which must be kept constant before the next study in order to avoid methodological biases.
- Conditions
- Morbid Obesity
- Being tested
- Study on insulin sensitivity after diet or bariatric surgery, gastric bypass
- Keywords
- Morbid obesity, Insulin resistance, Euglycemic clamp
- Medical subject headings
- Obesity, Morbid, Insulin Resistance
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Study on insulin sensitivity after diet or bariatric surgeryOther
Group A: 1 week of low calorie diet before gastric banding a new study 1 week after gastric banding Group B: 1 week of low calorie diet before gastric bypass a new study 1 week after gastric bypass
gastric bypassOther
Group B: 1 week of low calorie diet before gastric bypass a new study 1 week after gastric bypass
| Study group | Role | What they receive |
|---|---|---|
| 1 | group A: 10 morbidly obese subjects who will undergo gastric banding will be studied basally, 1 week after low-calorie diet and 1 week after operation. | |
| 2 | group B: 10 morbidly obese subjects who will undergo gastric bypass will be studied basally, 1 week after low-calorie diet and 1 week after operation. Receives: Other: Study on insulin sensitivity after diet or bariatric surgery; Other: gastric bypass |
What is being measured
The primary outcome is the main question the study is designed to answer.
Insulin sensibility pre and post bariatric surgery with euglycaemic hyperinsulinemic clamp (EHC)
Measured: 12 and 11 weeks before surgery and 1 week after surgery
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Feb 2010 (estimated)
- Study startFeb 2010
- Primary completionDec 2011
- Study completionJul 2012
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (6)Papers the sponsor has linked to this study.
- Other trials for Morbid ObesityStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Time perspective
- Prospective
- Enrolment
- 23 participants (actual)
Sponsor and investigators
- Lead sponsor
- Catholic University of the Sacred Heart
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Geltrude Mingrone, Catholic University of the Sacred Heart
- Investigators
- Geltrude Mingrone, MD, PhD, Principal investigator, Catholic University of Sacred Heart
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01063127
- Sponsor's protocol ID
- 749/09
- Status last verified
- Feb 2013
- First submitted
- 26 Jan 2010
- Last updated
- 15 Feb 2013
- Results posted
- No
- Data monitoring committee
- No
Publications
Guidone C, Manco M, Valera-Mora E, Iaconelli A, Gniuli D, Mari A, Nanni G, Castagneto M, Calvani M, Mingrone G. Mechanisms of recovery from type 2 diabetes after malabsorptive bariatric surgery. Diabetes. 2006 Jul;55(7):2025-31. doi: 10.2337/db06-0068.
PubMed 16804072Salinari S, Bertuzzi A, Iaconelli A, Manco M, Mingrone G. Twenty-four hour insulin secretion and beta cell NEFA oxidation in type 2 diabetic, morbidly obese patients before and after bariatric surgery. Diabetologia. 2008 Jul;51(7):1276-84. doi: 10.1007/s00125-008-1007-y. Epub 2008 May 6.
PubMed 18458872Mingrone G. Role of the incretin system in the remission of type 2 diabetes following bariatric surgery. Nutr Metab Cardiovasc Dis. 2008 Oct;18(8):574-9. doi: 10.1016/j.numecd.2008.07.004.
PubMed 18790374Ferrannini E, Mingrone G. Impact of different bariatric surgical procedures on insulin action and beta-cell function in type 2 diabetes. Diabetes Care. 2009 Mar;32(3):514-20. doi: 10.2337/dc08-1762. No abstract available.
PubMed 19246589Mingrone G, Castagneto M. Bariatric surgery: unstressing or boosting the beta-cell? Diabetes Obes Metab. 2009 Nov;11 Suppl 4:130-42. doi: 10.1111/j.1463-1326.2009.01120.x.
PubMed 19817795Gastaldelli A, Iaconelli A, Gaggini M, Magnone MC, Veneziani A, Rubino F, Mingrone G. Short-term Effects of Laparoscopic Adjustable Gastric Banding Versus Roux-en-Y Gastric Bypass. Diabetes Care. 2016 Nov;39(11):1925-1931. doi: 10.2337/dc15-2823. Epub 2016 Aug 29.
PubMed 27573937
Study at a glance
From the registry record, last updated by the sponsor on 15 Feb 2013. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Longitudinal, Open-label Study on the Short-term Effects of Roux-en-Y Gastric Bypass Surgery vs. Gastric Banding on Glucose Homeostasis in Obese Subjects
- ClinicalTrials.gov ID
- NCT01063127
- Acronym / sponsor ID
- 749/09
- Conditions
- Morbid Obesity
- Keywords
- Morbid obesity, Insulin resistance, Euglycemic clamp
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 23 participants (actual)
- Lead sponsor
- Catholic University of the Sacred HeartUniversity, hospital or other
- Study start
- Feb 2010
- Primary completion
- Dec 2011 (actual)
- Study completion
- Jul 2012 (actual)
- First posted
- 5 Feb 2010 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to quantify the relative contribution of improved insulin sensitivity and improved insulin secretion to the glycaemic effect of bariatric surgery.
Detailed description
In 1987 Pories et al. (1) published that after gastric bypass 99% of morbidly obese patients became and remained euglycaemic over time. However, the most interesting observation of these authors (1) was that the patients were converted to euglycaemia within 10 days of the operation, even if before they required large doses of insulin. Thereafter, we ourselves (2-6) as well as other Authors (7,8) have found that both mainly malabsorptive bariatric and mainly restrictive surgery are effective in producing early improvement/resolution of type 2 diabetes, also in normal weight (9) or overweight-obese subjects (10).
Until now the mechanisms through which bariatric surgery operate in improving insulin sensitivity and, consequently, diabetes control have not been elucidated. To complicate the picture there is the fact that after bariatric surgery patients are not allowed to eat for a time that is longer as the entity of the abdominal trauma increases. In fact, after laparoscopic bariatric surgery the patients are re-alimented in the 3rd post-operative day while after open surgery the time length before re-alimentation is about 7 days. Although in most centres the patients receive a parenteral nutrition covering the energy needs while they remain at rest, in some other centres they are only re-hydrated. Thus, it might be hypothesised that fasting can contribute to the improvement of glucose disposal. The data in the literature counteract this possibility as many Authors (11-15) have demonstrated that a very-low calorie diet (VLCD) is essentially unable to improve insulin sensitivity at least in the short run, when the weight loss is minimal. In this regard, Jazet et al. (11) found that the glucose control amelioration in diabetic subjects undergoing a 2-day VLCD was a reduction in the hepatic glucose production rather than an improvement in the whole-body glucose disposal. Similarly, Christiansen et al (12) observed the increase in the glucose metabolic clearance rate (MCR) was not apparent before day 20 of energy restriction, when the weight loss became significant. In another study, diabetic patients under a 4-day energy-restricted diet (providing 4620 ± 1050 kJ/d) had a deterioration of both basal glucose MCR and insulin-stimulated glucose disposal (13).
Recently, Laferrère et al (16) compared the late (1 month) effect of an equivalent weight loss by RYGB or by diet in two groups of matched morbidly obese patients with type 2 diabetes mellitus. The glucose area under-the-curve (AUC) after an oral glucose tolerance test (OGTT) and glucose levels at 120' were significantly lower after RYGB compared with diet (P = 0.014 and P = 0.001, respectively).
Another important aspect of the weight loss is the modulation of lipolysis. Many studies have shown that obese subjects are insulin resistant at the level of adipose tissue, ie, despite high plasma insulin levels lipolysis and FFA release are not suppressed. It is therefore interesting to study the changes in lipolysis before and after surgery and also the ability of insulin (e.g., during the euglycemic, hyperinsulinemic clamp) to suppress peripheral lipolysis. By infusing deuterated glycerol we will be able to estimate glycerol rate of appearance, which is the best available index of lipolysis. In fact intracellular triglyceride (TG) hydrolysis results in the release of one mole of glycerol and 3 moles of FFA. While the FFA can be re-esterified intracellularly, and thus do not appear into the systemic circulation, glycerol cannot be re-esterified since the adipocyte lacks glycerol kinase. Thus, all glycerol derived from intracellular TG hydrolysis is released into the circulation and can be traced by deuterated glycerol. We have used this technique previously in diabetic subjects (17), in subjects with NASH as well as in obese subjects under VLCD (18). In the latter study we have shown that VLCD improved adipose tissue IR.
As far as we know, no data are available in the literature comparing the effect of RYGB with a purely restrictive bariatric procedure in order to take into account simultaneously the effect of the surgical trauma and that of the reduced food intake in the early post-operative period.
The main goal of this study is to determine the immediate effect of Roux-en-Y gastric bypass surgery on glucose homeostasis, factoring out the confounding effects of the surgical approach (incl. laparoscopy) and of the post-operative fasting.
To this purpose, patients of the two bariatric surgery groups (Roux-en-Y gastric bypass and gastric banding) are matched as far as feasible. Primary parameter is insulin resistance (as assessed by Matsuda index). Further the same BMI inclusion criteria apply for both groups (BMI > 30 kg/m2 and < 55 kg/m2). While age, gender and BMI within the specified range are also expected to influence the read-outs, no matching for these baseline characteristics is foreseen due to feasibility issues.
Patients receive oral food typically from day 3 or 4 after laparoscopic bariatric surgery. This post-operative food intake is restricted to 800 - 1000 kcal/day, usually divided in 6 small meals, with the following composition 55% carbohydrates, 30% lipids and 15% proteins; saturated lipids ~ 10% . A similar caloric intake restriction will be imposed during the 1-week diet period prior to Visit 3, which will be done 10 +/- 2 weeks before the operation in order to allow the patients a complete recovery of his/her body weight which must be kept constant before the next study in order to avoid methodological biases.
Study design
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| 1 | – | –group A: 10 morbidly obese subjects who will undergo gastric banding will be studied basally, 1 week after low-calorie diet and 1 week after operation. |
| 2 | – | Other: Study on insulin sensitivity after diet or bariatric surgery, Other: gastric bypassgroup B: 10 morbidly obese subjects who will undergo gastric bypass will be studied basally, 1 week after low-calorie diet and 1 week after operation. |
Who may qualify
- Ages
- 25 to 55 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
- Study population
- Twenty morbidly obese subjects scheduled for RYGB or LAGB for will be included in the study.
Key inclusion criteria (6 listed)
- Morbidly obese subjects of both sexes with a BMI >40 kg/m2 who, for their obesity disease, are eligible for bariatric surgery and have accepted to undergo RYGB or LAGB
- Confirmed insulin resistance as assessed by Matsuda index
- Age 25-55 years
- Weight stable for at least 6 months before the study (+/- 5 kg within the previous 6 months)
- Stable medication
Key exclusion criteria (8 listed)
- Patients not eligible for laparoscopic RYGB or LAGB
- Incapacity to give a valid informed consent or unwilling to give the consent
- Pregnancy or lactating
- Patients eligible for RYGB/LAGB, but with:
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Study on insulin sensitivity after diet or bariatric surgeryGroup A: 1 week of low calorie diet before gastric banding a new study 1 week after gastric banding Group B: 1 week of low calorie diet before gastric bypass a new study 1 week after gastric bypass | Other | 2 |
| gastric bypassGroup B: 1 week of low calorie diet before gastric bypass a new study 1 week after gastric bypass | Other | 2 |
Primary outcome
Insulin sensibility pre and post bariatric surgery with euglycaemic hyperinsulinemic clamp (EHC)
Time frame: 12 and 11 weeks before surgery and 1 week after surgery
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 Feb 2013.
- Background: PubMed 16804072Guidone C, Manco M, Valera-Mora E, Iaconelli A, Gniuli D, Mari A, Nanni G, Castagneto M, Calvani M, Mingrone G. Mechanisms of recovery from type 2 diabetes after malabsorptive bariatric surgery. Diabetes. 2006 Jul;55(7):2025-31. doi: 10.2337/db06-0068.
- Background: PubMed 18458872Salinari S, Bertuzzi A, Iaconelli A, Manco M, Mingrone G. Twenty-four hour insulin secretion and beta cell NEFA oxidation in type 2 diabetic, morbidly obese patients before and after bariatric surgery. Diabetologia. 2008 Jul;51(7):1276-84. doi: 10.1007/s00125-008-1007-y. Epub 2008 May 6.
- Background: PubMed 18790374Mingrone G. Role of the incretin system in the remission of type 2 diabetes following bariatric surgery. Nutr Metab Cardiovasc Dis. 2008 Oct;18(8):574-9. doi: 10.1016/j.numecd.2008.07.004.
- Background: PubMed 19246589Ferrannini E, Mingrone G. Impact of different bariatric surgical procedures on insulin action and beta-cell function in type 2 diabetes. Diabetes Care. 2009 Mar;32(3):514-20. doi: 10.2337/dc08-1762. No abstract available.
- Background: PubMed 19817795Mingrone G, Castagneto M. Bariatric surgery: unstressing or boosting the beta-cell? Diabetes Obes Metab. 2009 Nov;11 Suppl 4:130-42. doi: 10.1111/j.1463-1326.2009.01120.x.
- Derived from this study: PubMed 27573937Gastaldelli A, Iaconelli A, Gaggini M, Magnone MC, Veneziani A, Rubino F, Mingrone G. Short-term Effects of Laparoscopic Adjustable Gastric Banding Versus Roux-en-Y Gastric Bypass. Diabetes Care. 2016 Nov;39(11):1925-1931. doi: 10.2337/dc15-2823. Epub 2016 Aug 29.
Related trials for Morbid Obesity
Not yet recruitingObservational study
Pilot Study on the Effectiveness and Safety of OPTILENE® SILVER MESH ELASTIC in Prevention of Surgical Site Infection (SSI) and Incisional Hernia (IH)
Abdominal Aortic Aneurysm, Morbid Obesity
Not yet recruitingObservational study
Evaluating Metabolic Health in Individuals With Extreme Obesity
BMI>40
Enrolling by invitationObservational study
Bariatric Surgery Registry
Obesity, Morbid
Not yet recruitingObservational study
Serum Estradiol and Endometrial Thickness After Bariatric Surgery in Postmenopausal Women With Obesity
Obesity, Morbid, Postmenopause
Active, not recruiting
Mindfulness Based Eating Awareness Training for Bariatric Surgery Patients
Obesity, Morbid, Eating Disorder Symptom
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Geltrude Mingrone, MD, PhD principal investigator
Catholic University of Sacred Heart
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Morbid Obesity, run by Catholic University of the Sacred Heart at 1 site in Italy.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 15 Feb 2013. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Insulin sensibility pre and post bariatric surgery with euglycaemic hyperinsulinemic clamp (EHC) (time frame: 12 and 11 weeks before surgery and 1 week after surgery). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT01063127, which also lists 6 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Feb 2013.